Avatar
Tonwhite9

0 Following 0 Followers
1
And mild psychological disturbances in healthy individuals. We hope that our results will raise the global awareness of the negative effects of haze on the physical and mental health of humans. Our findings provide guidance to the health authorities to focus on reducing physical symptoms, especially headache, eye, nose and throat discomfort and breathing difficulty, in order to reduce psychologica
1
Omen with bothersome symptoms first increased and then decreased. Conclusions: There was a notable variability in the development of disturbing vasomotor symptoms over time in a selected group of women aged 50?9. Population-based follow-up studies of untreated women would be useful to estimate the symptom burden. Keywords: Menopausal symptoms, Duration, Follow-up, EstoniaBackground A number of stu
1
Omen with bothersome symptoms first increased and then decreased. Conclusions: There was a notable variability in the development of disturbing vasomotor symptoms over time in a selected group of women aged 50?9. Population-based follow-up studies of untreated women would be useful to estimate the symptom burden. Keywords: Menopausal symptoms, Duration, Follow-up, EstoniaBackground A number of stu
1
En in the control groups (n = 486) were grouped by the number of years followed, with the prevalence and severity of symptoms calculated both cross-sectionally and longitudinally. Results: About two thirds of the women (67 ) reported vasomotor symptoms and half (46 ) bothersome symptoms at recruitment. In the cross-sectional analysis, their prevalence declined between recruitment and 1-year follow
1
Not included in the present analysis. The women in the blind arms received their drug bottles with coded labels (otherwise identical bottles). Women in the non-blind HT arm had their drug bottles marked with HT. Only data on women in blind placebo group and nontreatment group aged 50?9 at recruitment (n = 486) are used in this study. Throughout the trial, about 90 ofwomen in the non-treatment gro
1
Not included in the present analysis. The women in the blind arms received their drug bottles with coded labels (otherwise identical bottles). Women in the non-blind HT arm had their drug bottles marked with HT. Only data on women in blind placebo group and nontreatment group aged 50?9 at recruitment (n = 486) are used in this study. Throughout the trial, about 90 ofwomen in the non-treatment gro
1
Not included in the present analysis. The women in the blind arms received their drug bottles with coded labels (otherwise identical bottles). Women in the non-blind HT arm had their drug bottles marked with HT. Only data on women in blind placebo group and nontreatment group aged 50?9 at recruitment (n = 486) are used in this study. Throughout the trial, about 90 ofwomen in the non-treatment gro
1
Not included in the present analysis. The women in the blind arms received their drug bottles with coded labels (otherwise identical bottles). Women in the non-blind HT arm had their drug bottles marked with HT. Only data on women in blind placebo group and nontreatment group aged 50?9 at recruitment (n = 486) are used in this study. Throughout the trial, about 90 ofwomen in the non-treatment gro